M. Tracy

发表

Negative lusitropy and abnormal calcium handling in hypoxic cardiac myocytes exposed to the calcium-sensitizer EMD 53998.

K. Webster, D. J. Discher, N. Bishopric, 1993, Journal of molecular and cellular cardiology.

The relationship between tumour oxygenation determined by oxygen electrode measurements and magnetic resonance spectroscopy of the fluorinated 2-nitroimidazole SR-4554.

J. Griffiths, P. Workman, E. Aboagye, 1998, British Journal of Cancer.

Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxia.

J. Griffiths, P. Workman, E. Aboagye, 1997, Cancer research.

Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imagin

P. Workman, E. Aboagye, A. Kelson, 1998, Anti-cancer drug design.

Bioreductive metabolism of the novel fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitroimidazolyl) acetamide (SR-4554).

P. Workman, E. Aboagye, A. Lewis, 1997, Biochemical pharmacology.

Second-generation 1,2,4-benzotriazine 1,4-di-N-oxide bioreductive anti-tumor agents: pharmacology and activity in vitro and in vivo.

J. Brown, M. Lemmon, A. Minchinton, 1992, International journal of radiation oncology, biology, physics.

The pharmacokinetics, bioavailability and biodistribution in mice of a rationally designed 2-nitroimidazole hypoxia probe SR-4554.

P. Workman, E. Aboagye, K. Ryan, 1996, Anti-cancer drug design.

The novel fluorinated 2-nitroimidazole hypoxia probe SR-4554: reductive metabolism and semiquantitative localisation in human ovarian cancer multicellular spheroids as measured by electron energy loss spectroscopic analysis.

P. Workman, E. Aboagye, I. M. Huxham, 1995, British Journal of Cancer.

Development and validation of a solid-phase extraction and high-performance liquid chromatographic assay for a novel fluorinated 2-nitroimidazole hypoxia probe (SR-4554) in Balb/c mouse plasma.

P. Workman, E. Aboagye, M. Graham, 1995, Journal of chromatography. B, Biomedical applications.

Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors.

C. Koch, W. T. Jenkins, C. Chan, 1996, The Journal of pharmacology and experimental therapeutics.

Synthesis of anthracycline C-glycosyl isosteres

E. Acton, K. Ryan, S. Arora, 1986 .

Synthetic approach to anthracyclinone C-glycosides

E. Acton, K. Ryan, M. Tracy, 1985 .

Synthesis of tetrahydrobenzo[b]phenazines as anthracyclinone N-isosteres

E. Acton, M. Tracy, 1984 .

1,2,4-Benzotriazine 1,4-dioxides. An important class of hypoxic cytotoxins with antitumor activity.

K. Ryan, M. Dorie, A. Kelson, 1998, Anti-cancer drug design.

Structure-activity relationships for benzotriazine di-N-oxides.

M. Lemmon, J. Adams, C. Pearson, 1989, International journal of radiation oncology, biology, physics.

Synthesis of methotrexate-1-15N and methotrexate-4-15NH2

J. Arnold, G. Roberts, K. Ryan, 1989 .

A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy

M O Leach, I Judson, M Tracy, 2009, British Journal of Cancer.

Synthesis of [14C]anthracycline anticancer agent 14‐O‐(β‐alanyl‐N‐HCl)‐7‐O‐(2′,6′‐dideoxy‐2′‐fluoro‐α‐l‐talopyranosyl) adriamycinone‐14‐14C (DA‐125‐14C)

K. Ryan, L. Clizbe, A. Kelson, 1997 .

A theoretical investigation of the N-oxide moiety

A. Treasurywala, R. Perni, P. Kowalczyk, 1995 .